Cargando…

A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

INTRODUCTION: To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Chinese patients with type 2 diabetes (T2D). METHODS: In this phase 1, double-blind, placebo-controlled, multiple dose study, patients were randomized into one of two cohorts to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Ping, Sheng, Xiaoyan, Ji, Yongjia, Urva, Shweta, Wang, Feng, Miller, Sheila, Qian, Chenxi, An, Zhenmei, Cui, Yimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329955/ https://www.ncbi.nlm.nih.gov/pubmed/37285081 http://dx.doi.org/10.1007/s12325-023-02536-8

Ejemplares similares

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
por: Furihata, Kenichi, et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
por: Heise, Tim, et al.
Publicado: (2023)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
por: Frias, Juan Pablo, et al.
Publicado: (2020)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
por: Urva, Shweta, et al.
Publicado: (2020)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide
por: Wang, Jingyao, et al.
Publicado: (2022)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
por: Anala, Alekya Devi, et al.
Publicado: (2023)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
por: Yu, Yunfeng, et al.
Publicado: (2022)

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
por: Wadden, Thomas A., et al.
Publicado: (2023)

Weight loss efficiency and safety of tirzepatide: A Systematic review
por: Lin, Fei, et al.
Publicado: (2023)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
por: Sinha, Rachel, et al.
Publicado: (2023)

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
por: De Block, Christophe, et al.
Publicado: (2022)

Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
por: Dutta, Palak, et al.
Publicado: (2023)

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023)

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
por: le Roux, Carel W., et al.
Publicado: (2022)

Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
por: Karrar, Hani Raka, et al.
Publicado: (2023)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui, Yimin, et al.
Publicado: (2013)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
por: Sattar, Naveed, et al.
Publicado: (2022)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
por: Chiu, Nicholas, et al.
Publicado: (2022)

FRI483 Changes In Thyroid Function Test With Tirzepatide Use In Patients With Hypothyroidism
por: Kaylee Yu, Gayoung, et al.
Publicado: (2023)

Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Khan, Zarghuna, et al.
Publicado: (2023)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
por: Lingvay, Ildiko, et al.
Publicado: (2023)

Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
por: Samms, Ricardo J., et al.
Publicado: (2022)

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
por: El, Kimberley, et al.
Publicado: (2023)

FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report
por: Mathew, Anoopa, et al.
Publicado: (2023)

FRI612 Tirzepatide For The Treatment Of Post-bariatric Surgery Hypoglycemia And Early Dumping Syndrome
por: Frederick Stortz, Ethan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9mulm5bjs8umrbc2kpe2i7qq3j